The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.
 
Kristen M. Rosenthal
No Relationships to Disclose
 
Megan Cartwright
No Relationships to Disclose
 
Jerfiz D. Constanzo
No Relationships to Disclose
 
Hye Sook Chon
Honoraria - Curio Science; Envision Communications; Guidepoint Global; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Eisai; Envision Communications
Speakers' Bureau - Clinical Care Options
Travel, Accommodations, Expenses - Agenus
 
Linda R. Duska
Research Funding - Aduro Biotech (Inst); Arch Oncology (Inst); CE3 Inc (Inst); Clinipace Inc (Inst); Corcept Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Harpoon Therapeutics (Inst); K-Group Beta (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Lycera (Inst); Merck Sharp & Dohme (Inst); NRG Oncology (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); PSI Pharma Support America (Inst); Seattle Genetics/Astellas (Inst); Syndax (Inst)
Other Relationship - Agenus; Inovio Pharmaceuticals
 
Ebony R. Hoskins
No Relationships to Disclose
 
Ritu Salani
Consulting or Advisory Role - Eisai; GlaxoSmithKline/Tesaro; Immunogen; Karyopharm Therapeutics; Merck; Regeneron; Seagen
Travel, Accommodations, Expenses - GlaxoSmithKline